The Suitability of Sniff Dog as a Tool in Screening Tumors

NCT ID: NCT02049645

Last Updated: 2024-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies have demonstrated that sniff dogs can identify cancer patients from healthy subjects through sniffing exhaled breath air or blood or serum or urine or feces. It is hypothesized that sniff dogs may be used as a tool in screening cancer patients in health examination. Trained dogs will sniff serum from participants who are attending the annual health examination to identify potential or high risk subjects, and the results will be compared with the outcome of the traditional health examination, and the high risk subjects will be followed periodically for at least five years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

faculty staff and their adult family members

faculties and their adult family members of the Third Xiang-Ya Hospital

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* old than 20 years
* currently without cancer diagnosed with pathological examination
* allow the study team to examine his/her case history and incoming record

Exclusion Criteria

* cancer patients with pathological diagnosis
* who does not allow the study team to examine his/her case history and incoming record
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chang-Qing Gao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chang-Qing Gao

MD PhD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chang-Qing Gao, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Central South University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Third Xiang-Ya Hospital

Changsha, Hunan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chang-Qing Gao, MD PhD

Role: CONTACT

86 13974981039

Ya-Qin Wang, MD PhD

Role: CONTACT

86 15274810930

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chang-Qing Gao, MD PhD

Role: primary

86 139 7498 1039

Ya-Qin Wang, MD PhD

Role: backup

152 7481 0930

References

Explore related publications, articles, or registry entries linked to this study.

Ehmann R, Boedeker E, Friedrich U, Sagert J, Dippon J, Friedel G, Walles T. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respir J. 2012 Mar;39(3):669-76. doi: 10.1183/09031936.00051711. Epub 2011 Aug 18.

Reference Type BACKGROUND
PMID: 21852337 (View on PubMed)

Church J, Williams H. Another sniffer dog for the clinic? Lancet. 2001 Sep 15;358(9285):930. doi: 10.1016/S0140-6736(01)06065-2. No abstract available.

Reference Type BACKGROUND
PMID: 11575380 (View on PubMed)

Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, Church MR, Church JC. Olfactory detection of human bladder cancer by dogs: proof of principle study. BMJ. 2004 Sep 25;329(7468):712. doi: 10.1136/bmj.329.7468.712.

Reference Type BACKGROUND
PMID: 15388612 (View on PubMed)

McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther. 2006 Mar;5(1):30-9. doi: 10.1177/1534735405285096.

Reference Type BACKGROUND
PMID: 16484712 (View on PubMed)

Horvath G, Jarverud GA, Jarverud S, Horvath I. Human ovarian carcinomas detected by specific odor. Integr Cancer Ther. 2008 Jun;7(2):76-80. doi: 10.1177/1534735408319058. Epub 2008 May 27.

Reference Type BACKGROUND
PMID: 18505901 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Xiang-Ya 0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survival Outcomes of Lung Cancer
NCT03647098 RECRUITING